Literature DB >> 12565080

Comparison of late outcome in patients with versus without angina pectoris having reversible perfusion abnormalities during dobutamine stress technetium-99m sestamibi single-photon emission computed tomography.

Abdou Elhendy1, Arend F L Schinkel, Ron T van Domburg, Jeroen J Bax, Don Poldermans.   

Abstract

The aim of this study was to assess the prognostic significance of reversible perfusion abnormalities in patients without angina during dobutamine stress technetium-99m sestamibi single-photon emission computed tomography (SPECT). The study comprised 224 patients (age 60 +/- 11 years, 144 men) with completely or partially reversible perfusion abnormalities during dobutamine stress sestamibi SPECT. Follow-up end points were hard cardiac events (cardiac death and nonfatal myocardial infarction). Angina occurred in 93 patients (42%) during the dobutamine stress test (symptomatic ischemia group). The 131 patients without dobutamine-induced angina represented the silent ischemia group. There was no significant difference between patients with and without angina with regard to summed stress perfusion score (5.3 +/- 2.5 vs 5.2 +/- 2.2, p = 0.9) or summed ischemic score (3.1 +/- 1.7 vs 3.2 +/- 1.4, p = 0.7). During a median follow-up of 7.2 years, cardiac death occurred in 14 patients (15%) with and in 21 patients (16%) without angina. Nonfatal myocardial infarction occurred in 8 patients (9%) with and in 13 patients (10%) without angina. In a multivariate analysis model of clinical and perfusion data, independent predictors of cardiac events were age (hazard ratio 1.02, confidence intervals [CI] 1.01 to 1.05 per year increment), diabetes mellitus (hazard ratio 1.9, CI 1.2 to 3.4), and ischemic perfusion score (hazard ratio 2.1, CI 1.3 to 3.8). Patients with silent ischemia defined as reversible perfusion abnormalities without associated angina during dobutamine stress sestamibi SPECT imaging had similar incidences of ischemia and similar cardiac event rates compared with patients with symptomatic ischemia. Therefore, the absence of angina in association with reversible perfusion abnormalities should not be interpreted as a sign of a more benign prognosis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12565080     DOI: 10.1016/s0002-9149(02)03152-1

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  8 in total

Review 1.  Prognostic value of gated myocardial perfusion SPECT.

Authors:  Leslee J Shaw; Ami E Iskandrian
Journal:  J Nucl Cardiol       Date:  2004 Mar-Apr       Impact factor: 5.952

Review 2.  Silent myocardial ischemia: recent developments.

Authors:  Peter F Cohn
Journal:  Curr Atheroscler Rep       Date:  2005-03       Impact factor: 5.113

3.  Long term outcome in patients with silent versus symptomatic ischaemia during dobutamine stress echocardiography.

Authors:  E Biagini; A F L Schinkel; J J Bax; V Rizzello; R T van Domburg; B J Krenning; M Bountioukos; C Pedone; E C Vourvouri; C Rapezzi; A Branzi; J R T C Roelandt; D Poldermans
Journal:  Heart       Date:  2005-06       Impact factor: 5.994

4.  Silent ischemia: silent after all?

Authors:  Bianca D'Antono; Gilles Dupuis; André Arsenault; Denis Burelle
Journal:  Can J Cardiol       Date:  2008-04       Impact factor: 5.223

5.  Non-invasive cardiac assessment in high risk patients (The GROUND study): rationale, objectives and design of a multi-center randomized controlled clinical trial.

Authors:  Alexander M de Vos; Annemarieke Rutten; Hester J van de Zaag-Loonen; Michiel L Bots; Riksta Dikkers; Robert A Buiskool; Willem P Mali; Daniel D Lubbers; Arend Mosterd; Mathias Prokop; Benno J Rensing; Maarten J Cramer; H Wouter van Es; Frans L Moll; Eric D van de Pavoordt; Pieter A Doevendans; Birgitta K Velthuis; Albert J Mackaay; Felix Zijlstra; Matthijs Oudkerk
Journal:  Trials       Date:  2008-08-01       Impact factor: 2.279

6.  Development of a patient decision aid for people with refractory angina: protocol for a three-phase pilot study.

Authors:  Michael Hugh McGillion; Sandra Lee Carroll; Kelly Metcalfe; Heather Mary Arthur; Joseph Charles Victor; Robert McKelvie; Etienne Marc Jolicoeur; Marie-Gabrielle Lessard; James Stone; Nelson Svorkdal; John George Hanlon; Ada Andrade; Joel Niznick; Louise Malysh; William McDonald; Bonnie Stevens; Peter Coyte; Dawn Stacey
Journal:  Health Qual Life Outcomes       Date:  2014-06-11       Impact factor: 3.186

7.  Asymptomatic myocardial ischemia forecasts adverse events in cardiovascular magnetic resonance dobutamine stress testing of high-risk middle-aged and elderly individuals.

Authors:  R Brandon Stacey; Trinity Vera; Timothy M Morgan; Jennifer H Jordan; Matthew C Whitlock; Michael E Hall; Sujethra Vasu; Craig Hamilton; Dalane W Kitzman; W Gregory Hundley
Journal:  J Cardiovasc Magn Reson       Date:  2018-11-22       Impact factor: 5.364

8.  Comparison of Door-to-Balloon Time and 30-Day Mortality According to Symptom Presentation in Patients With Acute Myocardial Infarction.

Authors:  Takuya Nakahashi; Kenji Sakata; Jun Masuda; Naoto Kumagai; Takumi Higuma; Akiyoshi Ogimoto; Takashi Tanigawa; Hiroyuki Hanada; Mashio Nakamura; Masayuki Takamura; Kaoru Dohi
Journal:  Circ Rep       Date:  2021-03-19
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.